Zacks: Brokerages Expect Lipocine Inc (LPCN) Will Post Earnings of -$0.15 Per Share

Brokerages expect Lipocine Inc (NASDAQ:LPCN) to post ($0.15) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lipocine’s earnings. Lipocine reported earnings of ($0.13) per share in the same quarter last year, which would suggest a negative year over year growth rate of 15.4%. The business is scheduled to announce its next earnings results on Monday, May 6th.

On average, analysts expect that Lipocine will report full-year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.64) to ($0.50). For the next fiscal year, analysts expect that the company will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.21) to ($0.19). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Lipocine.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Wednesday, March 6th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.02).

Several research analysts have commented on LPCN shares. HC Wainwright set a $3.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Monday, November 19th. LADENBURG THALM/SH SH reissued a “buy” rating on shares of Lipocine in a research note on Thursday, January 17th. Finally, ValuEngine raised Lipocine from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Lipocine presently has a consensus rating of “Buy” and a consensus target price of $4.83.

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Lipocine by 145.8% in the third quarter. JPMorgan Chase & Co. now owns 95,429 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 56,606 shares during the period. Vanguard Group Inc. increased its stake in shares of Lipocine by 4.9% in the third quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after buying an additional 35,000 shares during the period. Finally, Vanguard Group Inc increased its stake in shares of Lipocine by 4.9% in the third quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after buying an additional 35,000 shares during the period. 9.82% of the stock is owned by institutional investors.

Shares of NASDAQ LPCN opened at $2.19 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 4.63 and a quick ratio of 4.63. The stock has a market cap of $49.31 million, a price-to-earnings ratio of -3.98 and a beta of 0.68. Lipocine has a 12 month low of $1.03 and a 12 month high of $2.64.

Lipocine Company Profile

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Further Reading: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.